Latest Period
Q1 2026
Security Snapshot
Spyre Therapeutics, Inc. - Common Stock, $0.0001 Par Value Per Share (SYRE) Institutional Ownership
CUSIP: 00773J202
13F Institutional Holders and Ownership History from Q3 2023 to Q1 2026
Institutions Reporting
196
Shares (Excl. Options)
82,649,625
Price
$50.44
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock, $0.0001 Par Value Per Share
- Symbol
- SYRE on Nasdaq
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 82,649,625
- Total 13F value
- $4,162,740,265
- Portfolio coverage rank
- 0%
- Share change
- +1,471,731
- Value change
- +$97,012,962
- Number of holders
- 196
- Shares outstanding
- 86,389,920
- SEC-reported price per share
- $75.04
- Insider filing price
- $75.04
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- SYRE - Spyre Therapeutics, Inc. - Common Stock, $0.0001 Par Value Per Share is tracked under CUSIP 00773J202.
- 196 institutions reported positions in Q1 2026.
- 6 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 152 to 196 between Q4 2025 and Q1 2026.
- SEC-reported value moved from $2,652,563,796 to $4,162,740,265.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 196 institutions filings for Q1 2026.
Security key
00773J202
Latest holder period
Q1 2026
13F holders
196
13D/G owners
6
CIK / CUSIP context first
Open Q1 2026 holders
SYRE full holder history
Spyre Therapeutics, Inc. SEC filings
Spyre Therapeutics, Inc. company facts
Spyre Therapeutics, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 00773J202:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
6
Security
SYRE
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Fairmount Funds Management LLC | 10% | 0% | $454,802,449 | +$45,891,321 | 9,016,702 | +11% | Peter Harwin | 16 Apr 2026 |
| PERCEPTIVE ADVISORS LLC | 5% | +15% | $217,875,378 | +$88,006,350 | 4,319,496 | +68% | Perceptive Advisors LLC | 15 Apr 2026 |
| BlackRock, Inc. | 6.6% | $59,323,024 | 3,962,635 | BlackRock, Inc. | 30 Jun 2025 | |||
| RTW INVESTMENTS, LP | 6.2% | $54,402,380 | 3,621,996 | RTW Investments, LP | 31 Dec 2024 | |||
| Venrock Healthcare Capital Partners III, L.P. | 4.6% | $40,335,429 | 2,685,448 | Venrock Healthcare Capital Partners III, L.P. | 31 Dec 2024 | |||
| TANG CAPITAL MANAGEMENT LLC | 2.4% | -58% | $62,064,160 | -$42,895,840 | 1,892,200 | -41% | TANG CAPITAL MANAGEMENT, LLC | 31 Dec 2025 |
As of 31 Mar 2026, 196 institutional investors reported holding 82,649,625 shares of Spyre Therapeutics, Inc. - Common Stock, $0.0001 Par Value Per Share (SYRE). This represents 96% of the company’s total 86,389,920 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
77%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| FMR LLC | 14% | 11,781,024 | +1.2% | 0.03% | $594,234,851 |
| BlackRock, Inc. | 6.4% | 5,521,221 | -0.02% | 0% | $278,490,385 |
| RTW INVESTMENTS, LP | 4.8% | 4,171,996 | 0% | 2.1% | $210,435,478 |
| Fairmount Funds Management LLC | 4.7% | 4,018,101 | 0% | 15% | $202,673,014 |
| PERCEPTIVE ADVISORS LLC | 4.4% | 3,783,225 | +23% | 3.8% | $190,825,869 |
| Venrock Adviser, LLC | 4.3% | 3,685,448 | 0% | 6.9% | $185,893,997 |
| VANGUARD CAPITAL MANAGEMENT LLC | 3.5% | 3,057,401 | 0% | 0% | $154,215,306 |
| Driehaus Capital Management LLC | 3.2% | 2,790,785 | -3.2% | 1% | $140,767,195 |
| STATE STREET CORP | 3% | 2,607,031 | +15% | 0% | $131,498,644 |
| Paradigm Biocapital Advisors LP | 2.3% | 1,957,266 | +33% | 2% | $98,724,497 |
| Commodore Capital LP | 2.2% | 1,912,380 | -20% | 5.6% | $96,460,447 |
| TCG Crossover Management, LLC | 2.2% | 1,900,582 | 0% | 2.7% | $95,865,356 |
| TANG CAPITAL MANAGEMENT LLC | 2.2% | 1,892,200 | 0% | 4.8% | $95,442,568 |
| WELLINGTON MANAGEMENT GROUP LLP | 2.1% | 1,824,811 | +18% | 0.02% | $92,043,467 |
| Capital International Investors | 2% | 1,746,129 | -50% | 0.02% | $88,074,747 |
| GEODE CAPITAL MANAGEMENT, LLC | 2% | 1,720,912 | +3.7% | 0.01% | $86,819,367 |
| JANUS HENDERSON GROUP PLC | 1.9% | 1,656,164 | -9.5% | 0.04% | $83,586,597 |
| RA CAPITAL MANAGEMENT, L.P. | 1.9% | 1,621,620 | 0% | 0.87% | $81,794,513 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 1.9% | 1,598,730 | -0.2% | 0.01% | $80,641,000 |
| Remedium Capital Partners, LLC | 1.7% | 1,456,231 | 0% | 26% | $73,452,292 |
| Affinity Asset Advisors, LLC | 1.5% | 1,279,134 | -11% | 3.8% | $64,519,519 |
| BANK OF AMERICA CORP /DE/ | 1.4% | 1,228,093 | +193% | 0% | $61,945,011 |
| BAKER BROS. ADVISORS LP | 1.2% | 1,000,000 | 0% | 0.29% | $50,440,000 |
| JPMORGAN CHASE & CO | 1.1% | 979,299 | +1456% | 0% | $44,479,761 |
| BRAIDWELL LP | 1.1% | 932,823 | -43% | 1.6% | $47,051,592 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
11
Latest
Q1 2026
Rows shown
1-11 of 11
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 82,649,625 | $4,162,740,265 | +$97,012,962 | $50.44 | 196 |
| 2025 Q4 | 80,976,878 | $2,652,563,796 | +$541,005,178 | $32.76 | 152 |
| 2025 Q3 | 64,298,657 | $1,077,601,900 | +$12,200,602 | $16.76 | 136 |
| 2025 Q2 | 63,624,754 | $952,552,077 | +$19,485,332 | $14.97 | 128 |
| 2025 Q1 | 62,108,053 | $1,004,204,799 | +$22,237,875 | $16.14 | 128 |
| 2024 Q4 | 59,883,954 | $1,394,038,124 | +$171,655,898 | $23.28 | 129 |
| 2024 Q3 | 51,375,323 | $1,511,815,633 | +$36,820,905 | $29.41 | 118 |
| 2024 Q2 | 50,382,939 | $1,184,222,119 | +$421,575,660 | $23.51 | 106 |
| 2024 Q1 | 31,640,426 | $1,196,964,043 | +$172,560,163 | $37.93 | 101 |
| 2023 Q4 | 28,010,905 | $600,997,673 | +$524,495,293 | $21.52 | 54 |
| 2023 Q3 | 3,257,983 | $39,909,852 | +$39,909,852 | $12.25 | 27 |